2) The treatment trial is led by Carmen Scheibenbogen and will be a follow-up study to the randomized Phase II trial of the CD19 antibody inebilizumab.
Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.